Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]

被引：0
|
作者：
Swinnen, Lode J. [1 ]
O'Neill, Anne [2 ]
Imus, Philip H. [1 ]
Gujar, Sachin [3 ]
Schiff, David [4 ]
Kleinberg, Lawrence [5 ]
Advani, Ranjana [6 ]
Dunbar, Erin [7 ]
Moore, Dennis F., Jr. [8 ]
Grossman, Stuart [1 ]
机构：
[1] Johns Hopkins, Med Oncol, Baltimore, MD USA
[2] Dana Farber Harvard Canc Ctr, BIostat Core, Cambridge, MA USA
[3] Johns Hopkins, Dept Radiol, Baltimore, MD USA
[4] Univ Virginia, Charlottesville, VA USA
[5] Johns Hopkins, Radiat Oncol, Baltimore, MD USA
[6] Stanford Canc Ctr, Stanford, CA USA
[7] Univ Florida, Gainesville, FL USA
[8] Wichita CCOP, Canc Ctr Kansas, Wichita, KS USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study
    Caroline Houillier
    Hervé Ghesquières
    Cécile Chabrot
    Carole Soussain
    Guido Ahle
    Sylvain Choquet
    Emmanuelle Nicolas-Virelizier
    Jacques-Olivier Bay
    Jacques Vargaftig
    Claude Gaultier
    Valérie Touitou
    Nadine Martin-Duverneuil
    Nathalie Cassoux
    Magali Le Garff-Tavernier
    Myrto Costopoulos
    Pierre Faurie
    Khê Hoang-Xuan
    Journal of Neuro-Oncology, 2017, 133 : 315 - 320
  • [22] Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study
    Houillier, Caroline
    Ghesquieres, Herve
    Chabrot, Cecile
    Soussain, Carole
    Ahle, Guido
    Choquet, Sylvain
    Nicolas-Virelizier, Emmanuelle
    Bay, Jacques-Olivier
    Vargaftig, Jacques
    Gaultier, Claude
    Touitou, Valerie
    Martin-Duverneuil, Nadine
    Cassoux, Nathalie
    Le Garff-Tavernier, Magali
    Costopoulos, Myrto
    Faurie, Pierre
    Hoang-Xuan, Khe
    JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (02) : 315 - 320
  • [23] Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiaiton temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results
    Glass, Jon
    Won, Minhee
    Schultz, Christopher J.
    Brat, Daniel
    Bartlett, Nancy
    Suh, John H.
    Fisher, Barbara Jean
    Liepman, Marcia K.
    Mehta, Minesh P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy
    Pels, H
    Schmidt-Wolf, IGH
    Glasmacher, A
    Schulz, H
    Engert, A
    Diehl, V
    Zellner, A
    Schackert, G
    Reichmann, H
    Kroschinsky, F
    Vogt-Schaden, M
    Egerer, G
    Bode, U
    Schaller, C
    Deckert, M
    Fimmers, R
    Helmstaedter, C
    Atasoy, A
    Klockgether, T
    Schlegel, U
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4489 - 4495
  • [25] Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience
    A. Silvani
    A. Salmaggi
    M. Eoli
    E. Lamperti
    G. Broggi
    C. E. Marras
    L. Fariselli
    I. Milanesi
    A. Fiumani
    P. Gaviani
    A. Erbetta
    A. R. Giovagnoli
    B. Pollo
    A. Botturi
    A. Boiardi
    Journal of Neuro-Oncology, 2007, 82 : 273 - 279
  • [26] Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience
    Silvani, A.
    Salmaggi, A.
    Eoli, M.
    Lamperti, E.
    Broggi, G.
    Marras, C. E.
    Fariselli, L.
    Milanesi, I.
    Fiumani, A.
    Gaviani, P.
    Erbetta, A.
    Giovagnoli, A. R.
    Pollo, B.
    Botturi, A.
    Boiardi, A.
    JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (03) : 273 - 279
  • [27] Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network
    Ghesquieres, Herve
    Houillier, Caroline
    Chinot, Olivier
    Choquet, Sylvain
    Molucon-Chabrot, Cecile
    Beauchene, Patrick
    Gressin, Remy
    Morschhauser, Franck
    Schmitt, Anna
    Gyan, Emmanuel
    Hoang-Xuan, Khe
    Nicolas-Virelizier, Emmanuelle
    Chevrier, Marion
    Savignoni, Alexia
    Turbiez, Isabelle
    Veillas, Florence
    Soumelis, Vassili
    Soussain, Carole
    BLOOD, 2016, 128 (22)
  • [28] Phase II trial of high-dose intravenous methotrexate (MTX) and rituximab with or without intraventricular DepoCyt in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)
    Fisher, Rebecca
    Glantz, Michael
    Blumenthal, Deborah
    Batten, Julia
    Van Horn, Alixis
    Chalmers, Lisa
    Chamberlain, Marc
    NEURO-ONCOLOGY, 2006, 8 (04) : 441 - 441
  • [29] Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study
    Kuitunen, Hanne K.
    Ronka, Aino L. K.
    Sonkajarvi, Eila M.
    Isokangas, Juha-Matti
    Pyorala, Marja
    Palosaari, Kari A. A.
    Jokimaki, Anna S.
    Partanen, Anu E.
    Littow, Harri J.
    Vakkala, Merja A.
    Jantunen, Esa J.
    Huttunen, Mirja E.
    Marin, Katja J.
    Aromaa-Hayha, Annikki M. K.
    Auvinen, Paivi K.
    Selander, Tuomas
    Puhakka, Inka K.
    Kuittinen, Outi M.
    CANCERS, 2023, 15 (04)
  • [30] Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1)
    Jahnke, K.
    Korfel, A.
    Martus, P.
    Lokka, S.
    Moehle, R.
    Griesinger, F.
    Rauch, M.
    Roeth, A.
    Hertenstein, B.
    Fischer, T.
    Hundsberger, T.
    Mergenthaler, H.
    Leithaeuser, M.
    Birnbaum, T.
    Herrlinger, U.
    Schubert, J.
    Florschuetz, A.
    Fischer, L.
    Weller, M.
    Thiel, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345